Sat, Dec 27, 2014, 1:22 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, Inc. Message Board

  • batzem batzem Dec 3, 2007 11:07 PM Flag

    Wachovia Report

    Starts coverage of SUPG with a market perform rating, Paraphrasing says they have spoken to many clinicians who all believe survivial benifit demonstrated by Vidaza is a a class effect and believe EORTC study will show a benifit but question the magnitude. Quoting " However concern resides in the fact that that the study has capped the maximum number of cycles at eight and there is a wide expectation that the median will actually be five cycles .As a result the protocol may have capped the potential survival advantages setting the stage for a less than optimal final result compared to Vidaza."
    Again paraphrasing state pipeline is intriguing but way to early to assign any value. Believe Cilag a very strong EU marketing partner and believe the next major potential for Supg is not till first half 09 when Dacogen is approved in EU.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
8.4950.0000(0.00%)Oct 10 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.